ADC Therapeutics SA
NYSE:ADCT
ADC Therapeutics SA
NYSE:ADCT
Price:
4.72 USD
-0.84%
Market Closed
Updated:
Apr 20, 2024
ADC Therapeutics SA
Total Liabilities
Last
Value
3-Years CAGR
5-Years CAGR
|
ADC Therapeutics SA
Total Liabilities Peer Comparison
Comparables:
ACIU
CRSP
BSLN
IDIA
KURN
Competitive Total Liabilities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Total Liabilities
$503m
|
CAGR 3-Years
41%
|
CAGR 5-Years
83%
|
CAGR 10-Years
N/A
|
|
|
AC Immune SA
NASDAQ:ACIU
|
Total Liabilities
CHf22.2m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Total Liabilities
$346.8m
|
CAGR 3-Years
28%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Total Liabilities
CHf183.3m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-2%
|
|
|
Idorsia Ltd
SIX:IDIA
|
Total Liabilities
CHf1.6B
|
CAGR 3-Years
23%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Total Liabilities
CHf14.8m
|
CAGR 3-Years
15%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
See Also
What is ADC Therapeutics SA's Total Liabilities?
Total Liabilities
503m
USD
503m
USD
Based on the financial report for Dec 31, 2023, ADC Therapeutics SA's Total Liabilities amounts to 503m USD.
What is ADC Therapeutics SA's Total Liabilities growth rate?
Total Liabilities CAGR 5Y
83%
83%
Over the last year, the Total Liabilities growth was 14%. The average annual Total Liabilities growth rates for ADC Therapeutics SA have been 41% over the past three years , 83% over the past five years .
You don't have any saved screeners yet
